Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 clinical trial of its lead drug candidate, Lucid-MS, for the treatment of multiple sclerosis (MS). The clearance follows the acceptance of the company's Investigational New Drug (IND) application, allowing the initiation of a randomized, double-blind, placebo-controlled study in people with MS.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (PAD2), an enzyme implicated in the breakdown of myelin, the protective sheath around nerve fibers. Unlike many existing MS therapies that broadly suppress the immune system, Lucid-MS aims to directly target demyelination, potentially offering a new mechanism of action that could halt or even reverse myelin damage. The drug candidate has previously completed Phase 1 testing in healthy volunteers, where it demonstrated a favorable safety and tolerability profile, according to the company.
The FDA clearance allows Quantum BioPharma to advance Lucid-MS into its first clinical testing in patients with MS. This milestone is significant for the company and the MS community, as there remains a high unmet need for treatments that address the underlying neurodegeneration rather than just managing symptoms. The editorial spotlight from BioMedWire highlights that Quantum BioPharma is also collaborating with researchers at Massachusetts General Hospital and Harvard Medical School to develop a PET imaging tracer that could quantify demyelination in real time, potentially aiding in the assessment of drug efficacy in future trials.
The coverage also notes that the company has attracted analyst attention, with Rodman & Renshaw initiating coverage on Quantum BioPharma with a Buy rating and a price target of $8 per share. This analyst endorsement comes as the company prepares to test Lucid-MS in the MS population, a significant step in its clinical development.
Quantum BioPharma is developing a portfolio of assets for neurodegenerative, metabolic, and alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on Lucid-MS, which has shown in preclinical models the ability to prevent and reverse myelin degradation. The company's broader pipeline includes UNBUZZD, a product for alcohol misuse, which has been spun out into a separate entity, Unbuzzd Wellness Inc., with Quantum retaining a 19.84% stake and royalty payment agreements.
The news of the FDA clearance comes amid a landscape of other biopharmaceutical companies working on neurological and other diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN). For Quantum BioPharma, this clearance represents a pivotal moment that could lead to new treatment options for the millions of people affected by MS worldwide.
Investors and industry watchers will be eager to see the results of the Phase 2 trial, as Lucid-MS's novel mechanism of action offers a differentiated approach that could potentially change the treatment paradigm for MS. For more information, visit the press release at https://ibn.fm/cwPHa and the company's newsroom at https://ibn.fm/QNTM.
